Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients with Hodgkin Lymphoma

Clinical Nuclear Medicine

Volumn 40, Issue 8, 2015, Pages e405-e410

  Rubello, Domenico ^a,d   Gordien, Pierre ^b   Morliere, Camille ^b   Guyot, Martine ^b   Bordenave, Laurence ^b   Colletti, Patrick M ^c   Hindie, Elif ^b  

^a 'Santa Maria della Misericordia' Hospital   (Italy)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

18F FDG; interim PET; liver; lymphoma; Positron emission tomography; SUV

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; VINBLASTINE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HODGKIN DISEASE; HUMAN; LEAN BODY WEIGHT; LIVER LOBE; LIVER SCINTISCANNING; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PET-CT SCANNER; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT RESPONSE; AGED; ANALYSIS OF VARIANCE; LIVER; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; AGED; ANALYSIS OF VARIANCE; BODY MASS INDEX; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LIVER; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEX FACTORS;

EID: 84938097716     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000828     Document Type: Article

References (31)

1. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21:841-854.
2. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clinical Oncol. 2014;32: 3048-3058.
3. Moulin-Romsee G, Hindie E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrowfindings in Hodgkin's lymphomamay circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37: 1095-1105.
4. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J ClinOncol. 2009;27:1906-1914.
5. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18 F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J NuclMed. 2010;51:1857-1862.
6. Barrington SF, QianW, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
7. Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010;51:2171-2180.
8. Choi Y, Hawkins RA, Huang SC, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med. 1994;35:818-823.
9. Iozzo P, Geisler F, Oikonen V, et al. Insulin stimulates liver glucose uptake in humans: an 18 F-FDG PET Study. J NuclMed. 2003;44:682-689.
10. Kamimura K, Nagamachi S, Wakamatsu H, et al. Associations between liver (18) F fluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome. Ann Nucl Med. 2010;24:157-161.
11. Kubota K, Watanabe H, Murata Y, et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nucl Med Biol. 2011;38:347-351.
12. Lin CY, Lin WY, Lin CC, et al. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clin imaging. 2011;35:437-441.
13. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
14. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-150S.
15. Viner M, Mercier G, Hao F, et al. Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. Radiology. 2013;267: 596-601.
16. Ceriani L, Suriano S, Ruberto T, et al. 18 F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med. 2012;37:949-952.
17. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850.
18. Groheux D, Delord M, Rubello D, et al. Variation of liver SUVon (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med. 2013;38:422-425.
19. Chiaravalloti A, Danieli R, Abbatiello P, et al. Factors affecting intrapatient liver and mediastinal blood pool F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123-1132.
20. Malladi A, Viner M, Jackson T, et al. PET/CT mediastinal and liver FDG uptake: effects of biological and procedural factors. JMed Imaging RadiatOcol. 2013; 57: 169-175.
21. Fencl P, Belohlavek O, Harustiak T, et al. The analysis of factors affecting the threshold on repeated 18 F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012;33:1188-1194.
22. Zhao S, Kuge Y, Tsukamoto E, et al. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun. 2002;23: 545-550.
23. Boktor RR, Walker G, Stacey R, et al. Reference range for intrapatient variability in blood-pool and liver SUV for 18 F-FDG PET. J NuclMed. 2013;54:677-682.
24. Keramida G, Potts J, Bush J, et al. Hepatic steatosis is associated with increased hepatic FDG uptake. Eur J Radiol. 2014;83:751-755.
25. Paquet N, Albert A, Foidart J, et al.Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J NuclMed. 2004;45:784-788.
26. Laffon E, Marthan R. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging. 2014; 41:2154.
27. Kanstrup IL, Klausen TL, Bojsen-Moller J, et al. Variability and reproducibility of hepatic FDG uptake measured as SUVas well as tissue-to-blood background ratio using positron emission tomography in healthy humans. Clin Physiol Funct Imaging. 2009;29:108-113.
28. CashenAF, Dehdashti F, Luo J, et al. 18 F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J NuclMed. 2011;52:386-392.
29. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim18 F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533.
30. Lin C, Itti E, Haioun C, et al. Early 18 F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J NuclMed. 2007;48:1626-1632.
31. Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim 18 F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J NuclMed. 2014;55:569-573.